⌘K
t
Venture Life Group PLC announced on 25 July 2025 the grant of options to subscribe for 2,500,000 ordinary shares of 0.3p each to its Directors. These options, transacted on 25 July 2024, were granted to Jerry Randall (1,000,000), Daniel Wells (1,000,000), and Paul McGreevy (500,000) at an exercise price of 57.70 pence per option. The options will vest after three years following the publication of the Company's annual results for 2027.
| Date | 25 Jul 2025 |
| Time | 07:05:00 |
| Category | Director/PDMR dealings |
| ID | 5153S |
25 July 2025
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Group")
Grant of Share Options
Venture Life (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that, pursuant to the Company's 2023 Long Term Incentive Plan ("LTIP"), it has granted options to subscribe for an aggregate of 2,500,000 ordinary shares of 0.3p each in the capital of the Company (the "Options") to the Company's Directors, as follows:
|
Director |
Number of Options Granted |
Exercise Price |
|
Jerry Randall |
1,000,000 |
57.70 pence |
|
Daniel Wells |
1,000,000 |
57.70 pence |
|
Paul McGreevy |
500,000 |
57.70 pence |
The Options (which are subject to malus and clawback provisions) will vest after three years following publication of the Company's annual results for 2027 and will be exercisable within 7 years of vesting. Vesting is conditional on the achievement of certain performance criteria which include a total shareholder return and earnings per share measurement.
Further detail is provided below in accordance with Article 19.3 of the EU Market Abuse Regulation.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Jerry Randall
|
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Executive Officer |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
Venture Life Group plc |
||||
|
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
||||
|
b)
|
Nature of the transaction
|
Grant of share options |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
||||
|
e)
|
Date of the transaction
|
25 July 2025 |
||||
|
f)
|
Place of the transaction
|
London Stock Exchange
|
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Daniel Wells
|
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Financial Officer |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
Venture Life Group plc |
||||
|
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
||||
|
b)
|
Nature of the transaction
|
Grant of share options |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
||||
|
e)
|
Date of the transaction
|
25 July 2024 |
||||
|
f)
|
Place of the transaction
|
London Stock Exchange
|
||||
|
|
|
|
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Paul McGreevy |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Non-Executive Chair |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
Venture Life Group plc |
||||
|
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
||||
|
b)
|
Nature of the transaction
|
Grant of share options |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
||||
|
e)
|
Date of the transaction
|
25 July 2024 |
||||
|
f)
|
Place of the transaction
|
London Stock Exchange
|
||||
|
|
|
|
||||
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500
Stephen Keys/George Lawson (Corporate Finance)
Michael Johnson (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.